X4 Pharmaceuticals, Inc — Director's Dealing 2017

Nov 16, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Arsanis, Inc. (ASNS)
CIK: 0001501697
Period of Report: 2017-11-15

Reporting Person: Alexandria Venture Investments, LLC (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series D convertible preferred stock	$		Common stock (225680.0)		Direct

Footnotes

F1: Not applicable

F2: Preferred shares are convertible at a ratio of 3.413 shares of preferred stock to 1 share of common stock